FONT-SIZE Plus   Neg

Roche, PTC Sign Deal To Advance Treatment For Spinal Muscular Atrophy

Roche Holding AG (RHHBY.PK), PTC Therapeutics, Inc. and the SMA Foundation, announced a licensing agreement for PTC's Spinal Muscular Atrophy, or SMA, programme. SMA is a genetic neuromuscular disorder that causes muscle weakness.

As per the terms of the agreement, Roche gains an exclusive worldwide license to PTC's SMA programme, which includes three compounds currently in preclinical development, as well as potential back-up compounds. PTC receives $30 million as an upfront payment, up to $460 million upon successful completion of certain development and commercialization milestones and up to double-digit royalties on commercial sales. PTC noted that development will be overseen by a joint steering committee comprised of members from Roche, PTC and the SMA Foundation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Railroad operator CSX Corp. (CSX), Tuesday reported a slight drop in profit for the third quarter, as revenues dropped 9 percent hurt largely by lower coal freight revenues. Nevertheless, earnings for the quarter trumped Wall Street estimates, while revenues fell short. Jacksonville, Florida-based... Intel Corp. (INTC), the world's biggest chipmaker, Tuesday reported a drop in profit for the third quarter, as personal computer sales continue to decline. Intel generates a chunk of its revenues by selling chips for computers, however, the company has been negatively impacted by slowing demand for... Earnings at banking giant JP Morgan Chase (JPM) jumped more than 20% compared to last year, despite a decline in revenue. The firm's bottom line received a boost from about $2 billion in tax benefits.
comments powered by Disqus
Follow RTT